{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-077264","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2022-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.916308+00:00","generated_at":"2026-06-26T22:24:27.256587+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali Therapeutics CFO Steve Krognes to join Board; COO Alex Schuth adds CFO role effective May 1, 2022","bullets":["Krognes transitions from CFO to Class III director as of May 1, 2022; his term expires at 2023 annual meeting.","Alexander Schuth, current COO and Secretary, becomes Chief Operating and Financial Officer on May 1, 2022.","No changes to Schuth's compensation in connection with his expanded role; Krognes to receive standard board cash and equity.","Krognes cited a personal desire to move back to Europe; Watts and Board expressed gratitude and support for continuity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-077264","json":"https://secwatch.observer/filing/0001193125-22-077264.json","markdown":"https://secwatch.observer/filing/0001193125-22-077264.md","text":"https://secwatch.observer/filing/0001193125-22-077264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/d310285d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:24:27.256587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0af693d1a1","claim":"Alexander Schuth was appointed as Chief Operating and Financial Officer at Denali Therapeutics Inc..","evidence_excerpt":"Alexander Schuth, M.D., current Chief Operating Officer and Secretary of the Company, will add the Chief Financial Officer role to his current responsibilities, becoming Denali’s Chief Operating and Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating and Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"2a16f5c7ce","claim":"Steve Krognes changed role as Chief Financial Officer at Denali Therapeutics Inc..","evidence_excerpt":"Steve Krognes will transition from his role as Chief Financial Officer to join the Company’s Board of Directors as of May 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b06aa174b8","claim":"Steve Krognes was appointed as Director at Denali Therapeutics Inc..","evidence_excerpt":"On March 14, 2022, Mr. Krognes was appointed to the Board, effective May 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000119312522077264/0001193125-22-077264-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}